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Background: Granulomatosis with polyangiitis (GPA) patients are prone to disease
relapses. We aimed to determine whether GPA patients at risk for relapse can be
identified by differences in B cell subset frequencies.
Methods: Eighty-five GPA patients were monitored for a median period of 3.1 years
(range: 0.1–6.3). Circulating B cell subset frequencies were analyzed by flow cytometry
determining the expression of CD19, CD38, and CD27. B cell subset frequencies
at the time of inclusion of future-relapsing (F-R) and non-relapsing (N-R) patients
were compared and related to relapse-free survival. Additionally, CD27+CD38hi B cells
were assessed in urine and kidney biopsies from active anti-neutrophil cytoplasmic
autoantibody-associated vasculitides (AAV) patients with renal involvement.
Results: Within 1.6 years, 30% of patients experienced a relapse. The CD27+CD38hi
B cell frequency at the time of inclusion was increased in F-R (median: 2.39%) compared
to N-R patients (median: 1.03%; p = 0.0025) and a trend was found compared with
the HCs (median: 1.33%; p = 0.08). This increased CD27+CD38hi B cell frequency at
inclusion was correlated to decreased relapse-free survival in GPA patients. In addition,
74.7% of patients with an increased CD27+CD38hi B cell frequency (≥2.39%) relapsed
during follow-up compared to 19.7% of patients with a CD27+CD38hi B cell frequency of
<2.39%. No correlations were found between CD27+CD38hi B cells and ANCA levels.
CD27+CD38hi B cell frequencies were increased in urine compared to the circulation,
and were also detected in kidney biopsies, which may indicate CD27+CD38hi B cell
migration during active disease.
Conclusions: Our data suggests that having an increased frequency of circulating
CD27+CD38hi B cells during remission is related to a higher relapse risk in GPA patients,
and thereforemight be a potential marker to identify those GPA patients at risk for relapse.
Keywords: vasculitis, granulomatosis with polyangiitis, ANCA, B cells, relapse
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INTRODUCTION
Anti-neutrophil cytoplasmic autoantibody (ANCA)-associated
vasculitides (AAV) are autoimmune diseases involving small-
to medium-sized blood vessels (1). AAV are classified
into granulomatosis with polyangiitis (GPA), microscopic
polyangiitis (MPA), and eosinophilic GPA (EGPA) (2). In
these patients, ANCA directed against proteinase 3 (PR3)
(3) or myeloperoxidase (MPO) (4) are frequently present.
PR3-ANCA are detected in the majority of GPA patients,
whereas MPO-ANCA are more often detected in MPA and
EGPA patients. PR3-ANCA-positive patients have a significantly
increased relapse rate compared to MPO-ANCA-positive
patients. Approximately 50% of the PR3-ANCA-positive patients
experience a relapse within 4 years of follow-up, compared to
25% of the MPO-ANCA-positive patients (5). Predicting relapses
remains pivotal for patient care, as relapses are associated with
considerable morbidity caused by both disease- and therapy-
related damage. So far, no biomarker for the prediction of relapse
has been found to be reliable in GPA patients. Combined data of
multiple studies has shown that ANCA titers can predict future
relapses only to a limited extent (6).
The clinical benefit observed in B cell depletion trials using
rituximab in patients with AAV strongly supports the contention
that B cells are key contributors in the AAV immunopathogenesis
(7–9). ANCA were detectable in the circulation of AAV patients
in remission and decreased 6 months after start of rituximab
treatment (7, 8). This suggests that clinical improvement seen
in rituximab-treated AAV patients precedes the reduction of
ANCA titers. Although disease relapses did occur in rituximab-
treated patients, these occurred only after B cell repopulation (8).
Together these results indicate that B cells may contribute to the
disease pathogenesis and relapses in an antibody-independent
manner. Importantly, B cells are the precursors of antibody- and
ANCA-producing plasma cells and might be correlated to the
occurrence of disease relapses in GPA patients. However, the
exact B cell subtype that can be used to predict GPA relapses
is undefined.
The B cell subset distribution in GPA patients has been found
to differ from that in healthy controls (HCs). Compared to HCs,
the frequencies of CD27+CD38−/+ memory and CD24hiCD27+
B cells were decreased, whereas CD27−CD38−/+ naïve B cells
were increased in GPA patients (10). In addition, the circulating
B cell phenotype of active GPA patients showed decreased
frequencies of CD24hiCD38hi and CD27−CD38hi transitional B
cells compared to remission patients (10). To our knowledge,
no studies assessed the CD27+CD38hi B cell frequencies in GPA
patients. Monitoring the B cell distribution in peripheral blood
might be a good prognostic tool to predict disease relapses
and could perhaps be more efficient than measuring serum
ANCA levels.
This study aimed to elucidate whether a specific subset of B
cells could be identified that is associated with risk for relapse
in GPA patients, and if monitoring these B cells could predict
the disease course in these patients. Furthermore, we assessed B
cell migration to the kidneys of active GPA patients with renal
involvement. B cell subset frequencies were determined in GPA
patients in remission, with and without future disease relapses,
and their relation to disease relapses and serum ANCA levels
was analyzed. Additionally, the B cell phenotype was investigated
in matched urine and blood samples and kidney biopsies from
active AAV patients with renal involvement.
METHODS
Study Population
Eighty-five GPA patients and 48 age-matched HCs (52.1% male,
median age: 57.3 years, range: 40–74) were enrolled in the
study between 2010 and 2013. This GPA patient cohort was
prospectively monitored. GPA diagnosis was based on definitions
described in the Chapel Hill Consensus Conference (2). At
inclusion, all patients were in complete remission [Birmingham
vasculitis activity score (BVAS)= 0]. Patients tested PR3-ANCA-
positive at least once during their disease course. None of the
patients or controls experienced an infection at the time of
sampling. Only patients that were at least ten months post-
rituximab treatment were included. Patients that experienced
a relapse during follow-up were designated to the future-
relapsing (F-R) group and the patients remaining in remission
were assigned to the non-relapsing (N-R) group. Diagnosis of
disease relapse was based on clinical judgment and had to
result in initiation/increase of immunosuppressive treatment.
Relapses were monitored in all patients andmedian time between
sampling and diagnosis of relapse was 1.6 years (range: 0.1–
3.8), whereas the total follow-up time for N-R patients was 3.3
years (range: 1.3–6.3). The main clinical and laboratory data of
the patients are summarized in Table 1. All patients and HCs
provided informed consent and all experimental procedures were
conducted according to the policies of the UMCG. The medical
ethics committee of the UMCG (Groningen, the Netherlands)
approved the study.
In addition to patients in remission, eleven AAV patients
(seven GPA and three MPA; Table 2) with clinical signs and
symptoms of active vasculitis with renal involvement were
included to assess their urine and blood samples simultaneously.
After additional diagnostic investigation, renal disease could be
confirmed for seven AAV patients (five GPA and two MPA).
Four active GPA patients with renal involvement were included
to assess plasma cell infiltration in kidney biopsies (Table 2).
Flow Cytometry Analysis of B Cell Subsets
EDTA venous blood was obtained from GPA patients and
HCs. Immediately after sampling, blood was washed twice in
PBS with 1% BSA (wash buffer). Next, 100 µl cell suspension
was stained using anti-human CD19-eFluor450, CD27-APC-
eFluor780, CD38-PE-Cy7 (eBiocience, San Diego, CA, USA)
or the corresponding isotype controls. Cells were treated with
10x FACS Lysing solution (BD Biosciences, San Jose, CA, USA)
and acquired on an LSR-II flow cytometer (BD Biosciences).
For all flow cytometry analyses, data were collected for at least
2∗105 cells, and analyzed using Kaluza 1.5a software (Beckman
Coulter, Brea, CA, USA). Supplementary Figure 1 shows the
gating strategy and Figure 1A the representative gating examples
for each group. The B cell subset percentages were converted to
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Subjects, n (% male) 58 (39.7) 27 (44.4) 0.7799
Age, mean (range) 59 (26–84) 55 (30–81) 0.3157
cANCA titer, median (range) 1:40 (0–1:640) 1:80 (0–1:640) 0.3149
cANCA positive (>1:20), n (%) 42 (66.7) 20 (74.1) 0.3478
Creatinine µmol/L, median (range) 72 (20–147) 73 (21–171) 0.2167
CRP mg/L, median (range) 4.9 (0.5–20) 4.9 (0.4–83) 0.5286
Disease duration in years, median (range) 9.3 (1.4–42.1) 11.4 (2.1–28.7) 0.3015
Number of total relapses before inclusion, median (range) 1 (0–6) 3 (0–10) 0.0001
Lymphocyte count * 106/L, median (range) 1,200 (340–2900) 695 (240–1,640) 0.003
B cell count * 106/L, median (range) 91 (4.1–510.8) 33.7 (1.3–246) 0.0017
CD19+ B cells (%), median (range) 8.1 (0.7–22.2) 3.9 (0.13–21.1) 0.0785
IS therapy at time of sampling, n (%) 22 (37.9) 19 (70.4) 0.0053
Azathioprine, n (%) 4 (6.8) 8 (29.6) 0.0051
Azathioprine + prednisolone, n (%) 8 (13.8) 6 (22.2) 0.3293
Cyclophosphamide + prednisolone, n (%) 1 (1.7) 0 (0) 0.4925
Mycophenolate mofetil + prednisolone, n (%) 3 (5.2) 4 (14.8) 0.1322
Prednisolone, n (%) 6 (10.3) 1 (3.7) 0.2998
Induction therapy
Azathioprine + prednisone, n (%) 2 (3.5) 0 (0) 0.3288
Cyclophosphamide + prednisone, n (%) 50 (86.2) 26 (96.3) 0.1593
Methotrexate + prednisone, n (%) 2 (3.5) 0 (0) 0.3288
Mycophenolate mofetil + prednisone, n (%) 0 (0) 1 (3.7) 0.1404
Cotrimoxazole, n (%) 4 (6.8) 0 (0) 0.1622
No. clinical manifestations baseline, median (range) 3 (1–6) 4 (1–6) 0.0104
Kidney involvement, n (%) 31 (57.1) 19 (70.4) 0.14
Airway involvement, n (%) 53 (91.4) 26 (96.3) 0.41
AAV, ANCA-associated vasculitides; cANCA, cytoplasmic anti-neutrophil cytoplasmic autoantibody; CRP, C-reactive protein; F-R, future-relapsing; IS, immunosuppressive; N-R,
non-relapsing; No., number. The bold values are the p-values that indicate a significant difference between the F-R and N-R group.
TABLE 2 | Clinical data and characteristics of AAV patients with active disease
and signs of renal involvement.
Urine analysis Plasma cell
histology




Age, median (range) 68 (59.9–82) 71.1 (59–86.4)
ANCA positive, n (%) 7 (100) 4 (100)
BVAS, median (range) 12 (11–21) 13 (11–15)
Creatinine umol/L, median (range) 174 (94–483) 236.5 (165–566)
CRP mg/L, median (range) 41 (6–85) 22 (6–85)
Proteinuria urine g/L, median (range) 1.22 (0.4–3.57) 2.5 (0.87–3.57*)
IS therapy, n (%) 3 (42.9) 2 (50)
No. clinical manifestations, median (range) 2 (1–4) 2 (1–2)
BVAS, Birmingham Vasculitis Activity Score; cANCA, cytoplasmic anti-neutrophil
cytoplasmic autoantibody; CRP, c-reactive protein; GPA, granulomatosis with polyangiitis;
IS, immunosuppressive; MPA, microscopic polyangiitis; No., number; *not determined for
1 patient.
absolute numbers using the lymphocyte count and the percentage
of total B cells. No lymphocyte counts were available for the
HC group.
Flow Cytometry Analysis of CD27+CD38hi
B Cells in Blood and Urine
Urine and blood samples were collected from ten AAV patients
with active disease. Urine samples were prepared as described
previously (11). Briefly, urine was diluted 1:1 in PBS and
centrifuged at 1,800 rpm. The sediment was resuspended in PBS
and mononuclear cells (MNCs) were isolated using lymphoprep
(Axis-Shield, Oslo, Norway). Next, MNCs were resuspended
in wash buffer and stained with anti-human CD19-PerCP-
Cy5.5, CD45-BV605, CD27-APC (BioLegend, San Diego, CA,
USA), CD3-BUV395, and CD38-BB515 (BD Biosciences) for
15min at room temperature in the dark. Isotype-matched
non-specific antibodies were used as negative controls. In
parallel, blood samples were labeled with the aforementioned
monoclonal antibodies. Afterwards, cells were treated with
10x diluted FACS lysing solution for 10min, washed twice
in wash buffer and immediately analyzed. Stained urine
and blood samples were acquired on the LSR-II and data
was analyzed using Kaluza 1.5a software. Figure 3A shows
a representative gating example of both blood and urine.
Three patients were excluded because no renal involvement
was diagnosed and accordingly no B cells were present in
the urine.
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FIGURE 1 | The CD27+CD38hi B cell frequency is increased in F-R patients. (A) Based on CD27 and CD38 expression, four subsets were distinguished: naive B
cells as CD27−CD38−/dim, transitional B cells as CD27−CD38hi, memory B cells as CD27+CD38−/dim and CD27+CD38hi B cells in HCs, N-R patients and F-R
patients. (B) The proportions of total B cells, transitional B cells, naïve B cells, and memory B cells are depicted for HCs, N-R patients and F-R patients. (C) The
CD27+CD38hi B cell frequency is expressed as a percentage within total B cells. The absolute CD27+CD38hi B cell count was calculated using the lymphocyte
count and CD27+CD38hi B cell frequency in F-R and N-R patients and is given as count*106/L peripheral blood. Red bars represent the median value. *p < 0.05;
**p < 0.01; ***p < 0.001; ****p < 0.0001.
Analysis of Plasma Cells in Kidney Biopsies
CD27+CD38hi B cells likely represent plasmablasts and/or
plasma cells (12, 13), however, determining CD38hi expressing
B cells in tissue is impossible as CD38 expression is not
unique for plasmablasts and distinguishing CD38+ and
CD38hi expression visually is arbitrary. Thus, kidney biopsies
of four active GPA patients with renal involvement were
stained for plasmablast and plasma cell infiltration using a
MUM1/IRF4 monoclonal antibody (clone MUM1p, DAKO,
Santa Clara, CA, USA) in an automated stainer (Ventana, Roche,
Basel, Switzerland).
Serum ANCA Levels
ANCA detection was performed by indirect
immunofluorescence, as described previously (14). ANCA
titers of 1:40 or higher were considered positive. Serum PR3-
ANCA levels could be determined in samples of 51 patients by
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Phadia ImmunoCAP R© 250 analyzer using EliA PR3S (Thermo
Fisher Scientific, Waltham, MA, USA).
In vitro PR3-ANCA and IgG
Peripheral blood mononuclear cells (PBMCs) were isolated and
cultured as described before (15). In short, for 79 GPA patients
PBMCs were available and were cultured for 12 days with
or without 3.2µg/mL CpG-ODN 2006 (Hycult Biotech, Uden,
the Netherlands), 100 ng/mL IL-21 (Immunotools, Friesoythe,
Germany) and 100 ng/mL BAFF (PeproTech Inc., Rocky Hill,
CT, USA). Stimulated and spontaneous PR3-ANCA (RU/mL)
production was determined in the supernatant by Phadia
ImmunoCAP R© 250 analyzer using EliA PR3S (Thermo Fisher
Scientific) and total spontaneous and stimulated IgG production
was assessed by ELISA. Five samples (2 F-R and 3 N-R) were
excluded because of a culture infection.
Statistical Analysis
Statistical analysis was performed using GraphPad Prism v7.0
(GraphPad Software, San Diego, CA, USA) and SPSS (IBM
Corporation, Chicago, IL, USA). B cell subset frequencies of HCs,
F-R andN-RGPA patients were compared using a KruskalWallis
test. Individual groups were compared with Dunn’s multiple
comparison test. The plasmablast counts were compared using
the MannWhitneyU-test. Furthermore, a KaplanMeier curve of
probability of relapse-free survival was plotted for patients with
less or more than 2.39% CD27+CD38hi B cells (one deceased
patient was excluded) and CD27+CD38hi B cell frequency was
compared between inclusion samples and samples before relapse
of F-R patients using the Wilcoxon signed rank test. For F-
R patients the mean difference between inclusion and the last
sample taken before relapse was 0.8 ± 0.5 years. Cox regression
analysis was performed to determine the relation between log-
transformed CD27+CD38hi B cells and immunosuppressive
treatment and relapse occurrence.
Correlations between different parameters were determined
with the Spearman r correlation. Finally, relapse-free survival was




During a median follow-up of 1.6 years, 27 GPA patients
experienced a disease relapse (future-relapsing; F-R), whereas
58 patients did not (non-relapsing; N-R). The number of
clinical manifestations at first diagnosis was higher in F-
R compared to N-R patients (Table 1). Additionally, F-R
patients had experienced more relapses than N-R patients
before study inclusion. At inclusion, more F-R patients received
immunosuppressive therapy. The cANCA titers and frequency of
patients with a positive cANCA titer did not differ between F-R
and N-R patients.
Induction therapy and other baseline clinical characteristics
such as C-reactive protein levels and serum creatinine did not
differ significantly between both patient groups (Table 1).
Increased Frequencies of Circulating
CD27+CD38hi B Cells in F-R Patients
The B cell phenotype was determined in 27 F-R and 58 N-R
patients in remission and in 48 HCs. For the F-R patient group
a median of 1,463 B cell events (range: 49–7,913) and for the N-R
patient group a median of 3,030 B cell events (range: 255–8,321)
were acquired on the flow cytometer. The total B cell frequency
was significantly lower in both patient groups compared to HCs
(Table 1 and Figure 1B). Analyzing B cell subsets, the transitional
B cell frequencies were not different between the groups. The
naïve B cell frequency was higher in both N-R and F-R patients
compared toHCs and the percentage ofmemory B cells was lower
in both patients groups as compared to HCs (Figure 1B), which
is in line with previously published results (10). The circulating
CD27+CD38hi B cell percentage was significantly increased in F-
R patients compared to N-R patients, while N-R patients were
similar to HCs (Figure 1C).
The lymphocyte and B cell count were significantly decreased
in F-R patients (Table 1). Using the lymphocyte count we
calculated the absolute numbers of circulating CD27+CD38hi B
cells. No differences in numbers of circulating CD27+CD38hi B
cells were observed between both patient groups (Figure 1C).
Cox regression analysis demonstrated a significant relation
between (log transformed) CD27+CD38hi B cells and relapse,
whereas only a trend between the use of immunosuppressive
medication and relapse was observed (Supplementary Table 1).
Increased Circulating CD27+CD38hi B Cell
Frequency in GPA Patients Is Related to
Decreased Relapse-Free Survival
Subsequently, we investigated whether an increased
CD27+CD38hi B cell frequency was related to future disease
relapse. We divided the GPA patients into two groups based on
the median CD27+CD38hi B cell frequency of the F-R patients:
one group consisted of patients with <2.39% and the other of
patients with 2.39% or more CD27+CD38hi B cells. Significantly
more patients with a high percentage of CD27+CD38hi B cells
experienced a future disease relapse than patients with a low
CD27+CD38hi B cell frequency (Figure 2A). The percentage of
patients (80.3%) who remained relapse-free during follow-up
was significantly higher in GPA patients with <2.39% circulating
CD27+CD38hi B cells compared to patients with ≥2.39%
CD27+CD38hi B cells (25.3%).
Moreover, during follow-up the circulating CD27+CD38hi B-
cell frequency in F-R patients tended to decrease 1–3 months
prior to relapse compared to remission samples (Figure 2B).
CD27+CD38hi B Cells Are Present in the
Kidney and Increased in the Urine of Active
AAV Patients With Renal Involvement
As the circulating CD27+CD38hi B cell frequency seemed to
decrease in GPA patients before relapse whereas this did not
occur in N-R patients over a period of 12 months (data not
shown), we hypothesized that CD27+CD38hi B cells migrate
to sites of inflammation. To explore this, we analyzed the
CD27+CD38hi B cell frequency in both the circulation and
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FIGURE 2 | An increased CD27+CD38hi B cell frequency is related to decreased relapse-free survival. (A) Percentage relapse-free survival is depicted in patients in
remission with < or ≥2.39% circulating CD27+CD38hi B cells (i.e., median value of F-R patients). Hazard ratio of 8.8 (95% CI: 3.35–23.2). The number of subjects at
risk are given for each time point in the table. (B) The CD27+CD38hi B cell frequency is expressed as a percentage within B cells during remission and 1–3 months
before relapse (n = 15). #p = 0.10, ****p < 0.0001.
urine of 10 active AAV patients. None of the three patients
without active renal involvement presented with B cells in the
urine. Whilst in the seven patients with active renal involvement
B cells could be detected in the urine, and contained an
increased proportion of CD27+CD38hi B cells compared to
the circulation (Figure 3B). Since CD27+CD38hi B cells likely
represent plasmablasts and plasma cells (12, 13) and proper
evaluation of CD38hi expressing B cells is impossible in tissue, we
stained four kidney biopsies using an antibody that detects the
MUM1/IRF4 transcription factor that is specifically expressed in
plasmablasts and plasma cells. Figure 3C demonstrates plasma
cell infiltration in the kidneys of four active GPA patients. For
two of these patients, the urinary CD27+CD38hi B cell frequency
was determined and this frequency was increased compared to
the circulation (Figure 3B). These findings might indicate that
CD27+CD38hi B cells migrate from the circulation to inflamed
kidneys during active disease.
CD27+CD38hi B Cell Frequency Is Not
Related to ANCA Levels in GPA Patients
As CD27+CD38hi B cells are likely the precursors of antibody-
producing plasma cells, and since we found evidence that the
CD27+CD38hi B cell frequency is related to future relapses,
we examined whether CD27+CD38hi B cell numbers and
percentages correlated with ANCA and total IgG levels. Such a
correlation could indicate that the increased CD27+CD38hi B cell
percentages are disease specific. No significant correlation was
found between the percentage of circulating CD27+CD38hi
B cells and ANCA titers (Supplementary Figure 2A).
Furthermore, no positive correlation was found between
serum PR3-ANCA levels, and the percentage or number
(data not shown) of circulating CD27+CD38hi B cells
(Supplementary Figure 2B). Similarly, the CD27+CD38hi
B cell frequency did not correlate with either spontaneous in
vitro produced (Supplementary Figure 2C), stimulated in vitro
produced PR3-ANCA (Supplementary Figure 2D), or total in
vitro spontaneous or stimulated IgG (data not shown).
DISCUSSION
In this study, we demonstrate an increase in the frequency of
circulating CD27+CD38hi B cells in GPA patients with future
relapses, and their association with an increased relapse risk. We
found that the circulating CD27+CD38hi B cell frequency tended
to decrease with impending relapse and detected CD27+CD38hi
B cells in the kidneys and urine of active patients with
renal involvement, suggesting migration of plasmablasts to
inflamed organs.
So far, multiple predictors of (future) disease activity
have been proposed, including platelet count (16) and lung
involvement at diagnosis (17). However, those markers are not
ideal since they only identify active disease or focus on a
subpopulation of patients. Currently, ANCA levels are the best
biomarker available to identify approaching disease relapses (6).
However, a disadvantage of ANCA levels as a biomarker is that it
is not reliable in all patients, which highlights the need for better
indicators of future disease activity. Here, we found that GPA
patients with increased frequencies of circulating CD27+CD38hi
B cells during remission were more likely to relapse in the
(near) future.
As circulating CD27+CD38hi B cells are likely the direct
precursors of (auto)antibody-producing plasma cells (18, 19),
they may play a major role in GPA pathogenesis. In other
autoimmune diseases such as SLE (20, 21), IgG4-related disease
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FIGURE 3 | Indication that CD27+CD38hi B cells migrate from the circulation to the kidney in active AAV patients with renal involvement. (A) Using CD27 and CD38,
the CD27+CD38hi B cell subset could be distinguished in both urine (right) and peripheral blood (left). (B) Circulating and urine CD27+CD38hi B cell percentage in
active patients with renal involvement (n = 4). (C) Immunohistochemistry for MUM1/IRF4, showing presence of plasma cells in formalin fixed paraffin embedded renal
biopsy tissue samples of four patients. *p = 0.03.
(22), and anti-PLA2R1 related membranous nephropathy (23)
the plasmablast frequency has been reported to be related
to disease activity, as were absolute plasmablast numbers
in SLE (20) and IgG4-related disease (22). Additionally,
plasmablast frequencies and numbers correlated significantly
with (auto)antibody levels in IgG4-related disease (22) and
SLE (20), although in one study on IgG4-related disease such
a correlation could not be confirmed (24). Interestingly, in
RA patients sorted plasmablasts were found to produce anti-
citrullinated protein antibodies (ACPA) with and without in
vitro stimulation. However, the authors did not study whether
the circulating plasmablasts correlated to serum ACPA levels
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(25). In the current study we did not find a correlation
between CD27+CD38hi B cells and ANCA titers, serum PR3-
ANCA levels or spontaneous and stimulated in vitro produced
PR3-ANCA. Previously it was shown that PR3-specific B cells
could be identified among switched memory B cells and
plasmablasts in higher numbers in active and remission PR3-
ANCA patients compared to HCs (26). In the current study
however, we compared secreted PR3-ANCA levels, whereas in
the study by Cornec et al. (26) B cells binding to PR3 were
stained. It might be that not all CD27+CD38hi B cells have
differentiated into plasma cells and/or must migrate to the
bone marrow in order to produce ANCA. Of note, although
CD27+CD38hi expression is found on precursors of plasma cells
(12, 13), these markers may also be expressed on memory B
cells (27). Another explanation might be that an increase in
CD27+CD38hi B cells is not disease-specific but a consequence
of smoldering inflammation. Indeed, plasmablasts of IgG4-
related disease patients express increased RNA levels of CD44
and SDC1 associated with cell migration and increased surface
marker levels of activation markers such as HLA-DR, CD95.
and CD86 (22). Additional evidence suggests that elevated IL-6
production by plasmablasts from RA patients induced increased
differentiation of T follicular helper cells, and that treatment
of RA patients with Tocilizumab decreased the circulating T
follicular helper cells in these patients (28). Previously, we
have also found that in vitro PR3-ANCA production is not
related to approaching relapses (29), which may also explain the
lack of correlation between CD27+CD38hi B cells and in vitro
ANCA production.
We demonstrated increased CD27+CD38hi B cell frequencies
in the kidney and urine of renal active AAV patients compared
to the circulation, which might indicate CD27+CD38hi B
cell migration from the circulation to the inflamed kidney.
Flow cytometric analysis demonstrated that the B cell subset
distribution in the circulation is different from that in the urine
samples, which suggests that there is active migration to the
kidney instead of leakage of CD27+CD38hi B cells into the
urine. In line with these observations are data from murine
lupus mouse models and SLE patients showing the presence
of plasma cells in the inflamed kidney (30, 31) and CXCR4+
plasma cells and plasmablasts in renal biopsies, respectively
(32). In Kawasaki disease, IgA plasma cell infiltration has
been demonstrated in the inflamed kidney as well as in other
affected organs (e.g., arteries and lungs) (33). Although B
cell and plasma cell infiltration in lesions of GPA patients
has been demonstrated before (34), to our knowledge, we are
the first to describe plasma cell infiltration into the inflamed
kidney in GPA. A recent article by Brix et al. described B
cell infiltrates in kidney biopsies from active ANCA-associated
glomerulonephritis patients and also found an association of
ectopic lymphoid structures with end stage renal disease during
follow-up (35). Identification of CD27+CD38hi B cells by
immunohistochemistry is technically challenging, since double
staining of the cell membrane is difficult to evaluate. In addition,
it is not possible to make a clear distinction between positive
and high CD38 expression. We used the MUM1/IRF4 protein
as a surrogate marker since it has the highest expression in
plasmablasts and plasma cells (36) and does not stain other cells
in kidney tissue.
An important limitation of the current study is the
assessment of total CD27+CD38hi B cells rather than PR3-
specific B cells. Additional limitations include the limited
number of patients in the study, the study design as it was
performed in a single center, and the limited material that
could be obtained for each patient resulting in a low number
of B cells that could be acquired in the flow cytometry
experiments. Importantly, a confounding factor might be recent
vaccinations as this might influence circulating CD27+CD38hi
B cell levels and this was not tracked by the hospital.
Future research should aim to include more patients to
assess the extent of plasma cell infiltration in the kidney and
the frequency of urinary CD27+CD38hi B cells and track
recent vaccinations.
In conclusion, in GPA patients an increased CD27+CD38hi
B cell frequency during remission might be associated with
future relapses of disease. Additional prospective studies
in larger GPA patient cohorts are needed to fully establish
whether the circulating CD27+CD38hi B cell frequency
during remission constitutes a novel prognostic marker of
disease activity.
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